Drugmaker AstraZeneca (AZN.L), opens new tab said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Lack of detailsDrugmaker AstraZeneca (AZN.L), opens new tab said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.
Lack of details
What details do you need? The article states that as of June 1st the price on AZ's entire respiratory products portfolio will be $35, including inhalers such as Airsupra, Bevespi Aerosphere and Breztri Aerosphere, and would be applicable for patients who are uninsured or underinsured.
Lack of details
And you will be on here pissing and moaning that you people don't qualifyReading comprehension is lacking in some of the folks here . . .
Lol ya for people with no insurance does nothing for anyone with MedicareWhat details do you need? The article states that as of June 1st the price on AZ's entire respiratory products portfolio will be $35, including inhalers such as Airsupra, Bevespi Aerosphere and Breztri Aerosphere, and would be applicable for patients who are uninsured or underinsured.
Lol ya for people with no insurance does nothing for anyone with Medicare